牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also...Show More
Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in financial performance for the period from January 1, 2023, to December 31, 2023. The company's sales surged by 31% in Danish kroner and 36% at constant exchange rates (CER), reaching DKK 232.3 billion. The operating profit followed suit, with a 37% increase in Danish kroner and a 44% rise at CER, amounting to DKK 102.6 billion. North America Operations saw a remarkable 50% growth in sales, while International Operations experienced an 11% increase. The Diabetes and Obesity care segment was a major contributor to this growth, with sales rising by 38% to DKK 215.1 billion, driven by GLP-1 diabetes sales and a staggering 147% increase in Obesity care sales. However, Rare disease sales saw a decrease of 16%. Novo Nordisk also completed significant clinical trials, including the first phase 3a trial with IcoSema and a phase 1 trial with oral amycretin. Looking ahead to 2024, the company anticipates sales growth of 18-26% at CER and operating profit growth of 21-29% at CER. The Board of Directors plans to propose a final dividend of DKK 6.40 per share for 2023 at the Annual General Meeting on March 21, 2024, and has initiated a new share repurchase programme of up to DKK 20 billion.
全球領先的醫療保健公司諾和諾德A/S報告稱，從2023年1月1日至2023年12月31日期間，財務業績大幅增長。該公司的銷售額以丹麥克朗計算增長了31％，按固定匯率（CER）計算增長了36％，達到2323億丹麥克朗。營業利潤緊隨其後，丹麥克朗增長了37％，按CER計算增長了44％，達到1,026億丹麥克朗。北美業務的銷售額顯著增長了50％，而國際業務的銷售額增長了11％。糖尿病和肥胖症護理板塊是這一增長的主要推動力，銷售額增長了38％，達到2151億丹麥克朗，這得益於 GLP-1 糖尿病銷售額和肥胖護理銷售額驚人的147％增長。但是，罕見病的銷售額下降了16％。諾和諾德還完成了重要的臨床試驗，...展開全部
全球領先的醫療保健公司諾和諾德A/S報告稱，從2023年1月1日至2023年12月31日期間，財務業績大幅增長。該公司的銷售額以丹麥克朗計算增長了31％，按固定匯率（CER）計算增長了36％，達到2323億丹麥克朗。營業利潤緊隨其後，丹麥克朗增長了37％，按CER計算增長了44％，達到1,026億丹麥克朗。北美業務的銷售額顯著增長了50％，而國際業務的銷售額增長了11％。糖尿病和肥胖症護理板塊是這一增長的主要推動力，銷售額增長了38％，達到2151億丹麥克朗，這得益於 GLP-1 糖尿病銷售額和肥胖護理銷售額驚人的147％增長。但是，罕見病的銷售額下降了16％。諾和諾德還完成了重要的臨床試驗，包括第一項針對icoSema的3a期試驗和一項口服阿米克雷汀的1期試驗。展望2024年，該公司預計，按CER計算，銷售額將增長18-26％，按CER計算，營業利潤將增長21-29％。董事會計劃在2024年3月21日的年度股東大會上提出2023年每股6.40丹麥克朗的末期股息，並啓動了一項高達200億丹麥克朗的新股票回購計劃。
有用
沒用